 Alexander Pearson
Concepts (266)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 14 | 2021 | 1002 | 2.590 |
Why?
| | Neoplastic Stem Cells | 9 | 2021 | 134 | 1.670 |
Why?
| | Medical Oncology | 3 | 2021 | 331 | 1.520 |
Why?
| | Salivary Gland Neoplasms | 6 | 2021 | 59 | 1.470 |
Why?
| | Oropharyngeal Neoplasms | 4 | 2022 | 116 | 1.440 |
Why?
| | Papillomavirus Infections | 4 | 2022 | 191 | 1.360 |
Why?
| | Carcinoma, Adenoid Cystic | 5 | 2018 | 23 | 1.300 |
Why?
| | Neoplasms | 8 | 2022 | 2670 | 1.050 |
Why?
| | Carcinoma, Papillary, Follicular | 1 | 2020 | 11 | 0.890 |
Why?
| | Diagnostic Tests, Routine | 1 | 2021 | 64 | 0.880 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2020 | 982 | 0.880 |
Why?
| | Specimen Handling | 1 | 2021 | 102 | 0.880 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 2020 | 14 | 0.870 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2020 | 33 | 0.870 |
Why?
| | Academies and Institutes | 1 | 2020 | 27 | 0.870 |
Why?
| | Microsatellite Instability | 4 | 2021 | 33 | 0.870 |
Why?
| | Carcinoma, Squamous Cell | 6 | 2017 | 1036 | 0.870 |
Why?
| | ras Proteins | 1 | 2020 | 133 | 0.820 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2020 | 134 | 0.810 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2020 | 308 | 0.790 |
Why?
| | Leadership | 1 | 2020 | 118 | 0.790 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2021 | 1207 | 0.770 |
Why?
| | Artificial Intelligence | 1 | 2020 | 206 | 0.750 |
Why?
| | Carcinoma | 1 | 2022 | 439 | 0.740 |
Why?
| | Carcinoma, Mucoepidermoid | 4 | 2019 | 16 | 0.700 |
Why?
| | Transcriptome | 2 | 2021 | 508 | 0.690 |
Why?
| | Lung Neoplasms | 2 | 2020 | 2116 | 0.680 |
Why?
| | Neoplasm Staging | 6 | 2022 | 1921 | 0.670 |
Why?
| | Cell Proliferation | 6 | 2021 | 1611 | 0.650 |
Why?
| | Papillomaviridae | 3 | 2022 | 139 | 0.640 |
Why?
| | Patient Selection | 1 | 2020 | 692 | 0.640 |
Why?
| | Thyroid Neoplasms | 1 | 2020 | 438 | 0.620 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2021 | 1179 | 0.610 |
Why?
| | Humans | 50 | 2022 | 83011 | 0.560 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 3 | 2018 | 30 | 0.520 |
Why?
| | Interleukin-6 | 3 | 2020 | 235 | 0.490 |
Why?
| | Xenograft Model Antitumor Assays | 9 | 2021 | 463 | 0.470 |
Why?
| | Tumor Burden | 4 | 2022 | 287 | 0.440 |
Why?
| | Mouth Neoplasms | 2 | 2021 | 180 | 0.390 |
Why?
| | Neoplasm Grading | 2 | 2020 | 321 | 0.380 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2021 | 272 | 0.360 |
Why?
| | Mice, SCID | 6 | 2018 | 240 | 0.350 |
Why?
| | Models, Biological | 3 | 2022 | 1797 | 0.350 |
Why?
| | Prognosis | 5 | 2022 | 3698 | 0.340 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2018 | 369 | 0.330 |
Why?
| | Antineoplastic Agents | 5 | 2020 | 2359 | 0.330 |
Why?
| | Mice | 16 | 2021 | 11116 | 0.310 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2019 | 1179 | 0.310 |
Why?
| | Cisplatin | 5 | 2022 | 582 | 0.290 |
Why?
| | Cell Line, Tumor | 10 | 2021 | 2421 | 0.290 |
Why?
| | Gene Expression Profiling | 2 | 2021 | 1367 | 0.290 |
Why?
| | Colorectal Neoplasms | 3 | 2021 | 854 | 0.280 |
Why?
| | Receptors, Interleukin-6 | 2 | 2021 | 17 | 0.280 |
Why?
| | Neoplasm Proteins | 2 | 2020 | 547 | 0.280 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 2309 | 0.270 |
Why?
| | Female | 22 | 2022 | 44686 | 0.260 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2020 | 937 | 0.260 |
Why?
| | Animals | 19 | 2021 | 26931 | 0.250 |
Why?
| | Male | 19 | 2022 | 41827 | 0.250 |
Why?
| | Cohort Studies | 5 | 2021 | 2704 | 0.250 |
Why?
| | Mutation | 4 | 2021 | 3851 | 0.240 |
Why?
| | Immunotherapy | 4 | 2022 | 571 | 0.240 |
Why?
| | Stomach Neoplasms | 2 | 2021 | 262 | 0.230 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2021 | 71 | 0.230 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2021 | 47 | 0.230 |
Why?
| | Drug Monitoring | 1 | 2022 | 120 | 0.220 |
Why?
| | Hypopharyngeal Neoplasms | 1 | 2020 | 14 | 0.220 |
Why?
| | Paclitaxel | 3 | 2022 | 464 | 0.220 |
Why?
| | Endogenous Retroviruses | 1 | 2020 | 9 | 0.220 |
Why?
| | DNA, Viral | 1 | 2022 | 281 | 0.220 |
Why?
| | Neck Dissection | 1 | 2021 | 73 | 0.220 |
Why?
| | Acetophenones | 1 | 2020 | 27 | 0.220 |
Why?
| | Proportional Hazards Models | 2 | 2020 | 870 | 0.220 |
Why?
| | Neoplasms, Experimental | 2 | 2020 | 284 | 0.210 |
Why?
| | 4-1BB Ligand | 1 | 2020 | 1 | 0.210 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2020 | 19 | 0.210 |
Why?
| | Wnt Signaling Pathway | 1 | 2021 | 86 | 0.210 |
Why?
| | Actomyosin | 1 | 2020 | 40 | 0.210 |
Why?
| | Laryngeal Neoplasms | 1 | 2020 | 85 | 0.210 |
Why?
| | Middle Aged | 13 | 2022 | 25580 | 0.210 |
Why?
| | User-Computer Interface | 1 | 2021 | 186 | 0.200 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2021 | 177 | 0.200 |
Why?
| | DNA Mutational Analysis | 1 | 2021 | 537 | 0.200 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2020 | 128 | 0.190 |
Why?
| | Cytoskeleton | 1 | 2020 | 190 | 0.190 |
Why?
| | Olfactory Mucosa | 1 | 2018 | 33 | 0.190 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 124 | 0.190 |
Why?
| | Cell Adhesion | 2 | 2020 | 427 | 0.190 |
Why?
| | Pyrrolidines | 1 | 2018 | 57 | 0.190 |
Why?
| | Gene Rearrangement | 1 | 2019 | 168 | 0.190 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2019 | 106 | 0.180 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2018 | 122 | 0.180 |
Why?
| | Early Detection of Cancer | 1 | 2021 | 312 | 0.180 |
Why?
| | Lymphocyte Activation | 1 | 2021 | 806 | 0.180 |
Why?
| | Computational Biology | 1 | 2021 | 529 | 0.170 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2019 | 157 | 0.170 |
Why?
| | Proto-Oncogene Proteins | 1 | 2021 | 677 | 0.170 |
Why?
| | Algorithms | 3 | 2020 | 1839 | 0.170 |
Why?
| | Gossypol | 1 | 2016 | 5 | 0.160 |
Why?
| | Epigenesis, Genetic | 1 | 2021 | 427 | 0.160 |
Why?
| | Logistic Models | 1 | 2020 | 1159 | 0.160 |
Why?
| | Protein Interaction Maps | 1 | 2016 | 49 | 0.160 |
Why?
| | Lymphocytes | 1 | 2018 | 475 | 0.160 |
Why?
| | Lymph Nodes | 1 | 2020 | 530 | 0.160 |
Why?
| | Salvage Therapy | 1 | 2017 | 224 | 0.160 |
Why?
| | Trans-Activators | 1 | 2019 | 446 | 0.160 |
Why?
| | Retinal Dehydrogenase | 1 | 2015 | 8 | 0.160 |
Why?
| | Immunoconjugates | 1 | 2016 | 113 | 0.150 |
Why?
| | Mesenchymal Stem Cells | 1 | 2018 | 290 | 0.150 |
Why?
| | Taxoids | 1 | 2016 | 131 | 0.150 |
Why?
| | Neoplasm Metastasis | 1 | 2020 | 1046 | 0.150 |
Why?
| | Mitosis | 1 | 2016 | 146 | 0.150 |
Why?
| | Biostatistics | 1 | 2015 | 20 | 0.150 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2021 | 672 | 0.150 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2016 | 578 | 0.150 |
Why?
| | Time Factors | 4 | 2020 | 5497 | 0.150 |
Why?
| | Cell Separation | 1 | 2016 | 215 | 0.150 |
Why?
| | Aniline Compounds | 1 | 2015 | 44 | 0.150 |
Why?
| | Risk Factors | 3 | 2021 | 5397 | 0.140 |
Why?
| | Statistics as Topic | 1 | 2015 | 242 | 0.140 |
Why?
| | Chemoradiotherapy | 3 | 2022 | 287 | 0.140 |
Why?
| | Isoenzymes | 1 | 2015 | 276 | 0.140 |
Why?
| | United States | 3 | 2022 | 6283 | 0.140 |
Why?
| | Crohn Disease | 1 | 2021 | 714 | 0.140 |
Why?
| | Colitis, Ulcerative | 1 | 2021 | 687 | 0.140 |
Why?
| | Membrane Glycoproteins | 1 | 2016 | 432 | 0.140 |
Why?
| | Brain Neoplasms | 1 | 2020 | 806 | 0.140 |
Why?
| | Tumor Cells, Cultured | 1 | 2016 | 1088 | 0.130 |
Why?
| | Drug Synergism | 3 | 2020 | 335 | 0.130 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2016 | 410 | 0.130 |
Why?
| | Aged | 6 | 2021 | 18477 | 0.130 |
Why?
| | Neoplasm Transplantation | 3 | 2020 | 400 | 0.130 |
Why?
| | Risk Assessment | 1 | 2021 | 2278 | 0.130 |
Why?
| | Retrospective Studies | 3 | 2021 | 7595 | 0.130 |
Why?
| | Sulfonamides | 1 | 2015 | 328 | 0.120 |
Why?
| | Ovarian Neoplasms | 1 | 2018 | 676 | 0.120 |
Why?
| | Methylmercury Compounds | 1 | 2009 | 3 | 0.100 |
Why?
| | Apoptosis | 4 | 2018 | 1773 | 0.100 |
Why?
| | Milk, Human | 1 | 2009 | 44 | 0.100 |
Why?
| | Disease Models, Animal | 3 | 2021 | 2299 | 0.100 |
Why?
| | Hair | 1 | 2009 | 59 | 0.100 |
Why?
| | Intelligence | 1 | 2009 | 72 | 0.090 |
Why?
| | Treatment Outcome | 5 | 2022 | 7876 | 0.090 |
Why?
| | Mice, Nude | 2 | 2020 | 785 | 0.090 |
Why?
| | Signal Transduction | 4 | 2021 | 3297 | 0.080 |
Why?
| | Models, Theoretical | 2 | 2022 | 485 | 0.080 |
Why?
| | Drug Administration Schedule | 2 | 2020 | 973 | 0.080 |
Why?
| | Endothelial Cells | 2 | 2020 | 402 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 2 | 2020 | 900 | 0.070 |
Why?
| | Cell Cycle | 2 | 2018 | 520 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2020 | 2100 | 0.070 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 1753 | 0.070 |
Why?
| | Disease-Free Survival | 2 | 2017 | 1195 | 0.070 |
Why?
| | Phenotype | 2 | 2021 | 2285 | 0.060 |
Why?
| | Adult | 5 | 2022 | 25950 | 0.060 |
Why?
| | Switzerland | 1 | 2021 | 15 | 0.060 |
Why?
| | Republic of Korea | 1 | 2021 | 29 | 0.060 |
Why?
| | Histological Techniques | 1 | 2021 | 33 | 0.060 |
Why?
| | Germany | 1 | 2021 | 68 | 0.060 |
Why?
| | Adolescent | 3 | 2022 | 9117 | 0.060 |
Why?
| | Alphapapillomavirus | 1 | 2021 | 34 | 0.060 |
Why?
| | Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2021 | 14 | 0.060 |
Why?
| | Italy | 1 | 2021 | 105 | 0.060 |
Why?
| | T Cell Transcription Factor 1 | 1 | 2021 | 18 | 0.060 |
Why?
| | Japan | 1 | 2021 | 293 | 0.060 |
Why?
| | Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 75 | 0.060 |
Why?
| | Shoulder | 1 | 2021 | 39 | 0.060 |
Why?
| | Hematoxylin | 1 | 2020 | 7 | 0.050 |
Why?
| | Eosine Yellowish-(YS) | 1 | 2020 | 9 | 0.050 |
Why?
| | Carboplatin | 1 | 2022 | 272 | 0.050 |
Why?
| | Induction Chemotherapy | 1 | 2022 | 137 | 0.050 |
Why?
| | TNF Receptor-Associated Factor 3 | 1 | 2020 | 2 | 0.050 |
Why?
| | Papillomavirus E7 Proteins | 1 | 2020 | 31 | 0.050 |
Why?
| | MutS Homolog 2 Protein | 1 | 2020 | 33 | 0.050 |
Why?
| | Oncogenic Viruses | 1 | 2020 | 4 | 0.050 |
Why?
| | HCT116 Cells | 1 | 2020 | 148 | 0.050 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2020 | 51 | 0.050 |
Why?
| | Drug Dosage Calculations | 1 | 2020 | 17 | 0.050 |
Why?
| | Forkhead Transcription Factors | 1 | 2021 | 155 | 0.050 |
Why?
| | Environmental Microbiology | 1 | 2020 | 29 | 0.050 |
Why?
| | Gastritis | 1 | 2020 | 26 | 0.050 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2020 | 98 | 0.050 |
Why?
| | Lymphocyte Depletion | 1 | 2020 | 99 | 0.050 |
Why?
| | Helicobacter Infections | 1 | 2020 | 34 | 0.050 |
Why?
| | Benchmarking | 1 | 2020 | 57 | 0.050 |
Why?
| | Tumor Virus Infections | 1 | 2020 | 82 | 0.050 |
Why?
| | Neoplasm Invasiveness | 1 | 2021 | 531 | 0.050 |
Why?
| | Feasibility Studies | 1 | 2022 | 751 | 0.050 |
Why?
| | Lymphatic Metastasis | 1 | 2021 | 507 | 0.050 |
Why?
| | Survivors | 1 | 2021 | 193 | 0.050 |
Why?
| | Probiotics | 1 | 2020 | 74 | 0.050 |
Why?
| | Symbiosis | 1 | 2020 | 98 | 0.050 |
Why?
| | Salivary Glands | 1 | 2018 | 19 | 0.050 |
Why?
| | Central Nervous System | 1 | 2020 | 148 | 0.050 |
Why?
| | Primary Cell Culture | 1 | 2018 | 78 | 0.050 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2019 | 359 | 0.050 |
Why?
| | Genetic Association Studies | 1 | 2020 | 291 | 0.050 |
Why?
| | Nasal Cavity | 1 | 2018 | 100 | 0.050 |
Why?
| | Young Adult | 2 | 2022 | 5959 | 0.040 |
Why?
| | ROC Curve | 1 | 2020 | 756 | 0.040 |
Why?
| | Actins | 1 | 2020 | 434 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2020 | 1073 | 0.040 |
Why?
| | Cytokines | 1 | 2021 | 748 | 0.040 |
Why?
| | Administration, Oral | 1 | 2018 | 726 | 0.040 |
Why?
| | Host-Pathogen Interactions | 1 | 2020 | 254 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2021 | 1553 | 0.040 |
Why?
| | Spiro Compounds | 1 | 2016 | 25 | 0.040 |
Why?
| | Cell Movement | 1 | 2020 | 743 | 0.040 |
Why?
| | Tissue Array Analysis | 1 | 2016 | 128 | 0.040 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2020 | 508 | 0.040 |
Why?
| | Benzodiazepines | 1 | 2016 | 62 | 0.040 |
Why?
| | G1 Phase | 1 | 2016 | 65 | 0.040 |
Why?
| | Survival Analysis | 1 | 2020 | 1585 | 0.040 |
Why?
| | Case-Control Studies | 1 | 2021 | 1825 | 0.040 |
Why?
| | Bacteria | 1 | 2020 | 440 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 1422 | 0.040 |
Why?
| | Databases, Factual | 1 | 2020 | 787 | 0.040 |
Why?
| | Cell Survival | 1 | 2018 | 1013 | 0.040 |
Why?
| | Neprilysin | 1 | 2015 | 40 | 0.040 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2017 | 249 | 0.040 |
Why?
| | STAT3 Transcription Factor | 1 | 2015 | 71 | 0.040 |
Why?
| | Analgesics, Opioid | 1 | 2020 | 372 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2018 | 314 | 0.040 |
Why?
| | Microcirculation | 1 | 2015 | 114 | 0.040 |
Why?
| | Severity of Illness Index | 1 | 2021 | 1777 | 0.040 |
Why?
| | Caspase 3 | 1 | 2015 | 175 | 0.040 |
Why?
| | Pyrroles | 1 | 2016 | 220 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2021 | 2969 | 0.040 |
Why?
| | Random Allocation | 1 | 2015 | 376 | 0.040 |
Why?
| | Decision Making | 1 | 2020 | 617 | 0.040 |
Why?
| | Publishing | 1 | 2015 | 90 | 0.040 |
Why?
| | Binding Sites | 1 | 2018 | 1122 | 0.040 |
Why?
| | DNA Damage | 1 | 2016 | 357 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2021 | 2665 | 0.040 |
Why?
| | Protein Binding | 1 | 2018 | 1504 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2018 | 1819 | 0.030 |
Why?
| | Microscopy, Fluorescence | 1 | 2015 | 443 | 0.030 |
Why?
| | Child | 2 | 2019 | 6720 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 3175 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2020 | 1211 | 0.030 |
Why?
| | Periodicals as Topic | 1 | 2015 | 168 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2015 | 724 | 0.030 |
Why?
| | Prospective Studies | 1 | 2022 | 4065 | 0.030 |
Why?
| | Computer Simulation | 1 | 2018 | 1058 | 0.030 |
Why?
| | Pilot Projects | 1 | 2015 | 829 | 0.030 |
Why?
| | Internet | 1 | 2015 | 320 | 0.030 |
Why?
| | Evidence-Based Medicine | 1 | 2015 | 451 | 0.030 |
Why?
| | Survival Rate | 1 | 2017 | 1918 | 0.030 |
Why?
| | Incidence | 1 | 2017 | 1637 | 0.030 |
Why?
| | Phosphorylation | 1 | 2015 | 1155 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2020 | 1519 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2018 | 1474 | 0.030 |
Why?
| | Adenocarcinoma | 1 | 2018 | 1194 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2018 | 1520 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2019 | 2213 | 0.030 |
Why?
| | Seychelles | 1 | 2009 | 2 | 0.020 |
Why?
| | Mercury | 1 | 2009 | 9 | 0.020 |
Why?
| | Seafood | 1 | 2009 | 9 | 0.020 |
Why?
| | Maternal Exposure | 1 | 2009 | 50 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2018 | 1464 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2019 | 6571 | 0.020 |
Why?
| | Internship and Residency | 1 | 2015 | 897 | 0.020 |
Why?
| | Aging | 1 | 2009 | 665 | 0.020 |
Why?
| | Infant | 1 | 2009 | 3085 | 0.010 |
Why?
| | Child, Preschool | 1 | 2009 | 3752 | 0.010 |
Why?
| | Brain | 1 | 2009 | 2156 | 0.010 |
Why?
|
|
Pearson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|